- Home
- NRDS vs REPL Comparison
NRDS vs REPL Comparison
Compare NRDS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRDS
- REPL
- Stock Information
- Founded
- NRDS 2009
- REPL 2015
- Country
- NRDS United States
- REPL United States
- Employees
- NRDS 650
- REPL N/A
- Industry
- NRDS EDP Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- NRDS Technology
- REPL Health Care
- Exchange
- NRDS Nasdaq
- REPL Nasdaq
- Market Cap
- NRDS 616.0M
- REPL 578.4M
- IPO Year
- NRDS 2021
- REPL 2018
- Fundamental
- Price
- NRDS $8.54
- REPL $8.00
- Analyst Decision
- NRDS Buy
- REPL Strong Buy
- Analyst Count
- NRDS 5
- REPL 6
- Target Price
- NRDS $17.00
- REPL $20.00
- AVG Volume (30 Days)
- NRDS 540.9K
- REPL 967.9K
- Earning Date
- NRDS 04-28-2025
- REPL 05-15-2025
- Dividend Yield
- NRDS N/A
- REPL N/A
- EPS Growth
- NRDS N/A
- REPL N/A
- EPS
- NRDS 0.38
- REPL N/A
- Revenue
- NRDS $687,600,000.00
- REPL N/A
- Revenue This Year
- NRDS $12.65
- REPL $31.16
- Revenue Next Year
- NRDS $8.37
- REPL N/A
- P/E Ratio
- NRDS $22.47
- REPL N/A
- Revenue Growth
- NRDS 14.71
- REPL N/A
- 52 Week Low
- NRDS $7.55
- REPL $4.92
- 52 Week High
- NRDS $16.45
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- NRDS 43.07
- REPL 36.82
- Support Level
- NRDS $8.18
- REPL $6.44
- Resistance Level
- NRDS $8.92
- REPL $7.97
- Average True Range (ATR)
- NRDS 0.55
- REPL 0.73
- MACD
- NRDS 0.08
- REPL 0.08
- Stochastic Oscillator
- NRDS 46.26
- REPL 41.47
About NRDS NerdWallet Inc.
Nerdwallet Inc is a company that provides onsumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.